Unmet Need
Next-generation vaccines are needed to address the emergence of new pathogens, the limitations of current vaccine technologies, and the need for more effective and durable immunity against complex diseases like cancer, HIV, and emerging viruses. Traditional vaccines require long production timelines, often require cold storage, multiple doses, and may not provide long-lasting immunity. Therefore, there is a strong need for novel vaccine platforms to be developed to generate more effective immune responses and more accessible vaccines for a range of diseases.
Technology Description
Researchers at Johns Hopkins have developed a series of DNA vectors, cell lines, and exosomes, all created with the goal of generating an exosome-based vaccine platform that induces strong immune responses to the SARS-CoV-2 Spike protein. It includes DNA vectors for the inducible or constitutive expression of SARS-CoV-2 Spike proteins, cell lines that express these proteins, and exosomes produced by these cell lines that display significant levels of SARS-CoV-2 Spike at their surface. These exosomes, upon injection into animals, induce strong anti-Spike immune responses to any form of Spike, including Delta and Omicron.
Value Proposition
Stage of Development
